Kamran Sajadi, MD
Urogynecology and Reconstructive Pelvic Surgery · Portland, ORNPI 1508986530
Payments from drug & device makers
What this record shows
8 manufacturers reported payments, led by Axonics, Inc. at 34.1% of the total. Reporting peaked in 2024 at $3,104 and has fallen 90.3% since, to $301 in 2025.
Across 41 payments — averaging $112.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$2K
- Procept Biorobotics Corporation$1K
- Medtronic$1K
- Teleflex LLC$255
- Boston Scientific$157
- Neotract Inc.$144
- plus $119 from 2 others
What the payments were for
- Travel & lodging$2,65157%
- Food & beverage$1,96843%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 13 | $1,577 |
| Procept Biorobotics Corporation | 10 | $1,364 |
| Medtronic(2 entities) | 9 | $1,002 |
| Teleflex LLC | 2 | $255 |
| Boston Scientific | 4 | $157 |
| Neotract Inc. | 1 | $144 |
| Coloplast | 1 | $75 |
| Antares Pharma, Inc. | 1 | $44 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$1,188
- AQUABEAM SYSTEM$1,179
- INTERSTIM$936
- Bulkamid$611
- UroLift$247
- UroLift System$152
How this compares
Too few urogynecology and reconstructive pelvic surgery providers in Oregonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 127 | $91,432 |
| GemtesaVibegron | 77 | $44,465 |
| Estradiol | 52 | $4,911 |
| Oxybutynin Chloride ErOxybutynin Chloride | 78 | $2,364 |
| Trospium Chloride ErTrospium Chloride | 13 | $2,083 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 43 | $996 |
| Tamsulosin Hcl | 71 | $862 |
| Finasteride | 18 | $253 |
| Cephalexin | 27 | $202 |
| Oxybutynin Chloride | 21 | $184 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $46 |
| Diazepam | 12 | $39 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in Portland
- Sarah BoylesPortland$2K
- Bhumy HelikerPortland$2K
- Leah PosthumaPortland$2K
- Ian FieldsPortland$619
- Sara CichowskiPortland$393
- Blake OsmundsenPortland$293
- Mary DenmanPortland$209
- Audrey TarrPortland$176
- William GregoryPortland$154
- Susan HobsonPortland$125
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.